Consumption soothing and vulnerability in the Zone Lacustre, Mali

"This paper explores risk sharing in the Zone Lacustre, Mali, as viewed through the lens of consumption smoothing. We find that idiosyncratic shocks appear to have little impact on consumption, and that households respond to these shocks in a variety of ways. In general, nonpoor households are more likely to enter into new income-generating activities while poor households are more likely to engage in credit or gift exchange or to ration consumption. When we construct a stronger test for consumption smoothing, we find that changes in household income lead to modest changes in consumption. Covariant shocks, as measured by village/round dummies, always lead to changes in consumption. These results are robust to concerns regarding bias resulting from measurement error or endogeneity of changes in income. Lastly, we find that households with access to improved water control infrastructure are less vulnerable than those that rely on rainfall or the flooding of the Niger River." Authors' AbstractVulnerability ,Consumption shocks ,

Consumption soothing and vulnerability in the Zone Lacustre, Mali

"This paper explores risk sharing in the Zone Lacustre, Mali, as viewed through the lens of consumption smoothing. We find that idiosyncratic shocks appear to have little impact on consumption, and that households respond to these shocks in a variety of ways. In general, nonpoor households are more likely to enter into new income-generating activities while poor households are more likely to engage in credit or gift exchange or to ration consumption. When we construct a stronger test for consumption smoothing, we find that changes in household income lead to modest changes in consumption. Covariant shocks, as measured by village/round dummies, always lead to changes in consumption. These results are robust to concerns regarding bias resulting from measurement error or endogeneity of changes in income. Lastly, we find that households with access to improved water control infrastructure are less vulnerable than those that rely on rainfall or the flooding of the Niger River." Authors' AbstractVulnerability ,Consumption shocks ,

National patterns of functional diversity and redundancy in predatory ground beetles and bees associated with key UK arable crops

1. Invertebrates supporting natural pest control and pollination ecosystem services are crucial to world-wide crop production. Understanding national patterns in the spatial structure of natural pest control and pollination can be used to promote effective crop management and contribute to long-term food security. 2. We mapped the species richness and functional diversity of ground beetles and bees to provide surrogate measures of natural pest control and pollination for Great Britain. Func- tional diversity represents the value and range of morphological and behavioural traits that support ecosystem services. We modelled the rate at which functional diversity collapsed in response to species extinctions to provide an index of functional redundancy. 3. Deficits in functional diversity for both pest control and pollination were found in areas of high arable crop production. Ground beetle functional redundancy was positively corre- lated with the landscape cover of semi-natural habitats where extinctions were ordered by body size and dispersal ability. For bees, functional redundancy showed a weak positive cor- relation with semi-natural habitat cover where species extinctions were ordered by feeding specialization. 4. Synthesis and applications. Increasingly, evidence suggests that functionally diverse assem- blages of ground beetles and bees may be a key element to strategies that aim to support pol- lination and natural pest control in crops. If deficits in both functional diversity and redundancy in areas of high crop production are to be reversed, then targeted implementation of agri-environment schemes that establish semi-natural habitat may provide a policy mecha- nism for supporting these ecosystem services

'My teeth don't chew on shrapnel': an anthology of poetry by military veterans

This anthology, created by Oxford Brookes Poetry Centre, features poetry written by participants and associates of the Oxford Brookes Veterans' Poetry Workshop, 2019-20. Nine poets are represted here: Jo Young, Tom Laaser, Claire Hughes, Noel Harrower, John Thampi, Jamie Broady, Andrew Fassett, Stewart Hill, and Maggs Vibo. The anthology also includes an introduction by Niall Munro, an explanation of the workshop process by Susie Campbell, an essay about women veteran writers by Jane Potter, and reflections on her research into the perceptions of veterans in the UK and the US by Rita Phillips. Susie Campbell has also provided helpful writing prompts linked to the poems for those readers who are - or would like to be - writers. In addition to the four versions of the anthology, this package of files also includes transcripts of each of the interviews conducted by Dr Niall Munro with ten workshop participants, not all of whom appear in the anthology: Eugene Ratz, John Thampi, J. Robin Whitely, Jo Young (two interviews), Andrew Fassett, Tom Laaser, Stewart Hill, Claire Hughes, Maggs Vibo, and Jamie Broady. The transcriptions were completed by Dr Hester Bradley

Australian bat lyssavirus infection in two horses

In May 2013, the first cases of Australian bat lyssavirus infections in domestic animals were identified in Australia. Two horses (filly-H1 and gelding-H2) were infected with the Yellow-bellied sheathtail bat (YBST) variant of Australian bat lyssavirus (ABLV). The horses presented with neurological signs, pyrexia and progressing ataxia. Intra-cytoplasmic inclusion bodies (Negri bodies) were detected in some Purkinje neurons in haematoxylin and eosin (H&E) stained sections from the brain of one of the two infected horses (H2) by histological examination. A morphological diagnosis of sub-acute moderate non-suppurative, predominantly angiocentric, meningo-encephalomyelitis of viral aetiology was made. The presumptive diagnosis of ABLV infection was confirmed by the positive testing of the affected brain tissue from (H2) in a range of laboratory tests including fluorescent antibody test (FAT) and real-time PCR targeting the nucleocapsid (N) gene. Retrospective testing of the oral swab from (H1) in the real-time PCR also returned a positive result. The FAT and immunohistochemistry (IHC) revealed an abundance of ABLV antigen throughout the examined brain sections. ABLV was isolated from the brain (H2) and oral swab/saliva (H1) in the neuroblastoma cell line (MNA). Alignment of the genome sequence revealed a 97.7% identity with the YBST ABLV strain

Correction to: Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature.

The original version of this article unfortunately contained a mistake. Oliver Hanemann name was incorrect in the in the acknowledgements section of this paper

Guidelines on the management of abnormal liver blood tests

These updated guidelines on the management of abnormal liver blood tests have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG. The original guidelines, which this document supersedes, were written in 2000 and have undergone extensive revision by members of the Guidelines Development Group (GDG). The GDG comprises representatives from patient/carer groups (British Liver Trust, Liver4life, PBC Foundation and PSC Support), elected members of the BSG liver section (including representatives from Scotland and Wales), British Association for the Study of the Liver (BASL), Specialist Advisory Committee in Clinical Biochemistry/Royal College of Pathology and Association for Clinical Biochemistry, British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN), Public Health England (implementation and screening), Royal College of General Practice, British Society of Gastrointestinal and Abdominal Radiologists (BSGAR) and Society of Acute Medicine. The quality of evidence and grading of recommendations was appraised using the AGREE II tool. These guidelines deal specifically with the management of abnormal liver blood tests in children and adults in both primary and secondary care under the following subheadings: (1) What constitutes an abnormal liver blood test? (2) What constitutes a standard liver blood test panel? (3) When should liver blood tests be checked? (4) Does the extent and duration of abnormal liver blood tests determine subsequent investigation? (5) Response to abnormal liver blood tests. They are not designed to deal with the management of the underlying liver disease.</p

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen

Glastir Monitoring & Evaluation Programme. First year annual report

The Welsh Government has commissioned a comprehensive new ecosystem monitoring and evaluation programme to monitor the effects of Glastir, its new land management scheme, and to monitor progress towards a range of international biodiversity and environmental targets. A random sample of 1 km squares stratified by landcover types will be used both to monitor change at a national level in the wider countryside and to provide a backdrop against which intervention measures are assessed using a second sample of 1 km squares located in areas eligible for enhanced payments for advanced interventions. Modelling in the first year has forecast change based on current understanding, whilst a rolling national monitoring programme based on an ecosystem approach will provide an evidence-base for on-going, adaptive development of the scheme by Welsh Government. To our knowledge, this will constitute the largest and most in-depth ecosystem monitoring and evaluation programme of any member state of the European Union

Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature (vol 267, pg 607, 2020)

The original version of this article unfortunately contained a mistake. Oliver Hanemann name was incorrect in the in the acknowledgements section of this paper